Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Jul 2021 11:42

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Read more
9 Jul 2021 10:20

Open Orphan subsidiary scores 'significant contract' with AIM ImmunoTech

(Sharecast News) - Clinical research organisation Open Orphan's hVIVO subsidiary has signed "a significant contract" to test AIM ImmunoTech's antiviral candidate, Ampligen.

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
17 Jun 2021 14:05

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Read more
17 Jun 2021 11:43

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Read more
16 Jun 2021 16:00

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

Read more
10 May 2021 13:37

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

Read more
10 May 2021 09:30

Open Orphan subsidiary signs contract to make Covid-19 challenge virus

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a contract with Imperial College London, as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.

Read more
6 May 2021 15:33

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

Read more
9 Apr 2021 10:33

Open Orphan launches new data platform to combat infectious diseases

Open Orphan launches new data platform to combat infectious diseases

Read more
26 Mar 2021 14:36

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

Read more
25 Mar 2021 17:14

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

Read more
25 Mar 2021 15:34

Open Orphan makes progress with Covid-19 characterisation study

(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.